Company: AZN
Filing Date: 2025-09-22
Form Type: 6-K
Source: 0001654954-25-010967
Chunk: 0

Company: ASTRAZENECA PLC
Filing Date: 2025-09-22
Form: 6-K
Chunk 0
---
#### FORM 6-K
<div align='center'>SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Report of Foreign Issuer

Pursuant to Rule 13a-16 or 15d-16 of

the Securities Exchange Act of 1934

For the month of September2025

Commission File Number: 001-11960</div>

#### AstraZeneca PLC
<div align='center'>1 Francis Crick Avenue

Cambridge Biomedical Campus

Cambridge CB2 0AA

United Kingdom

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.

Form 20-F X Form 40-F __

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):

Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ______

Indicate by check mark whether the registrant by furnishing the information contained in this Form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.

Yes __ No X

If “Yes” is marked, indicate below the file number assigned to the Registrant in connection with Rule 12g3-2(b): 82-_____________</div>

#### AstraZeneca PLC
<div align='center'>INDEX TO EXHIBITS</div>

#### 1.
**Tezspire Recommended for Approval in EU for CRSwNP**

22 September 2025

<div align='center'>**Tezspire recommended for approval in the EU by CHMP for chronic rhinosinusitis with nasal polyps

Recommendation based on WAYPOINT Phase III trial results showing Tezspire reduced nasal polyp severity and nasal congestion, nearly eliminated the need for surgery and significantly reduced systemic corticosteroid use vs. placebo**</div>

AstraZeneca and Amgen's Tezspire (tezepelumab) has been recommended for approval in the European Union (EU) for the treatment of adult patients with chronic rhinosinusitis with nasal polyps (CRSwNP).

The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion